Every article, report, and earnings note where MRNA appears.
Moderna, Inc. (MRNA) slumps after a massive one-day surge sparked by positive Phase 3 melanoma data for its personalized cancer vaccine with Merck. The pullback looks like profit-taking after a historic repricing, even as the clinical win strengthens Moderna’s long-term oncology story.
Moderna, Inc. (MRNA) explodes after Merck collaboration data showed positive Phase 3 melanoma results for its personalized cancer vaccine. The stock surged in extended trading as investors priced in a possible new oncology growth engine, though the company remains unprofitable and valuation now looks stretched.
Moderna is a Hold as mNEXSPIKE gains traction and the pipeline advances, but shrinking revenue, heavy losses, and negative free cash flow keep the story high risk.
Moderna’s latest drop looks more like regulatory panic than a broken thesis. With an Aug. 5 FDA decision now in sight and the flu program still under active review, the selloff looks overdone.
Moderna’s latest surge looks earned, not speculative. Science Day gave the market a concrete post-COVID roadmap, and the August 5 flu decision gives MRNA a real catalyst investors can actually underwrite.
Moderna, Inc. (MRNA) rises sharply after Science Day gave investors a clearer growth roadmap beyond COVID. The company outlined potential launches in 2027 and 2028, reaffirmed a path to cash breakeven by 2028, and got a price-target boost from Piper Sandler.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate MRNA ReportCancel anytime